Investment Landscape: RNA-Based Therapeutics for Neurodegenerative Diseases
Overview
flowchart TD
therapeutics["therapeutics"] -->|"protects against"| age_related_cognitive_decline["age-related cognitive decline"]
therapeutics["therapeutics"] -->|"inhibits"| neuroinflammation["neuroinflammation"]
Therapeutics["Therapeutics"] -->|"references"| SIRT6["SIRT6"]
Therapeutics["Therapeutics"] -->|"references"| AADC["AADC"]
Therapeutics["Therapeutics"] -->|"references"| CX3CR1["CX3CR1"]
Therapeutics["Therapeutics"] -->|"references"| BACE1["BACE1"]
Therapeutics["Therapeutics"] -->|"references"| APOE["APOE"]
Therapeutics["Therapeutics"] -->|"references"| VCP["VCP"]
Therapeutics["Therapeutics"] -->|"references"| GFAP["GFAP"]
Therapeutics["Therapeutics"] -->|"references"| NURR1["NURR1"]
Therapeutics["Therapeutics"] -->|"references"| BDNF["BDNF"]
Therapeutics["Therapeutics"] -->|"references"| NLRP3["NLRP3"]
Therapeutics["Therapeutics"] -->|"references"| TFEB["TFEB"]
Therapeutics["Therapeutics"] -->|"references"| PPARGC1A["PPARGC1A"]
style therapeutics fill:#4fc3f7,stroke:#333,color:#000
Investment Landscape: RNA-Based Therapeutics covers the current R&D investment, clinical trial pipeline, and funding trends for RNA-based therapeutic approaches in neurodegenerative diseases including Alzheimer's Disease, Parkinson's Disease, ALS, Frontotemporal Dementia, and Huntington's Disease.
Last updated: 2026-03-17 14:50 PT
Clinical Trial Pipeline
...Investment Landscape: RNA-Based Therapeutics for Neurodegenerative Diseases
Overview
Mermaid diagram (expand to render)
Investment Landscape: RNA-Based Therapeutics covers the current R&D investment, clinical trial pipeline, and funding trends for RNA-based therapeutic approaches in neurodegenerative diseases including Alzheimer's Disease, Parkinson's Disease, ALS, Frontotemporal Dementia, and Huntington's Disease.
Last updated: 2026-03-17 14:50 PT
Clinical Trial Pipeline
Total Clinical Trials: 187
Active Trials (Recruiting/Active): 42
Trial Phases
| Phase | Count |
|-------|-------|
| PHASE1 | 28 |
| PHASE1, PHASE2 | 15 |
| PHASE2 | 31 |
| PHASE2, PHASE3 | 4 |
| PHASE3 | 12 |
| PHASE4 | 3 |
| NA | 94 |
Trial Status
| Status | Count |
|--------|-------|
| RECRUITING | 24 |
| ACTIVE_NOT_RECRUITING | 11 |
| NOT_YET_RECRUITING | 7 |
| COMPLETED | 89 |
| TERMINATED | 18 |
| WITHDRAWN | 8 |
RNA Therapeutic Modalities
- Antisense Oligonucleotides (ASO): 67 trials
- RNA Interference (RNAi): 23 trials
- MicroRNA-based therapies: 18 trials
- mRNA therapeutics: 12 trials
- Aptamers: 4 trials
- Splice-modulating RNAs: 12 trials
Disease-Specific Pipeline
Alzheimer's Disease (AD)
RNA therapeutics for AD remain in early-stage development compared to small molecule and antibody approaches. Key targets include:
- Tau pathology: BIIB080 (IONIS-MAPT) - Phase 1/2[@biib]
- [Amyloid precursor protein](/entities/app-protein) (APP): Various ASO approaches in preclinical
- APOE4: Gene silencing strategies under development
Current AD trials using RNA approaches:
31 trials (6.3% of total AD pipeline of ~4,910 trials)
Parkinson's Disease (PD)
RNA therapeutics in PD focus on:
- [alpha-Synuclein](/proteins/alpha-synuclein): ASO and RNAi approaches targeting SNCA gene[@alphasynuclein]
- LRRK2: Genetic approaches for LRRK2-associated PD
- GBA1: Gene therapy for Gaucher's-associated PD
Current PD trials:
24 trials (4.8% of total PD pipeline)
Amyotrophic Lateral Sclerosis (ALS)
ALS has the most advanced RNA therapeutic pipeline:
- Tofersen (BIIB067): Approved for SOD1-ALS[@tofersen]
- WVE-004: [C9orf72](/entities/c9orf72)-targeting ASO - Phase 1/2[@wve]
- ATXN2: Targeting ATXN2 expansion - Phase 1/2
- FUS: FUS-ALS ASO approaches in development
Current ALS trials:
52 trials (significantly higher proportion relative to disease size)
Frontotemporal Dementia (FTD)
RNA approaches for FTD are emerging:
- C9orf72: Shared target with ALS - ASO in development[@wve]
- [MAPT](/proteins/tau): Tau-targeting ASOs for 4R-tauopathies
- GRN: Progranulin-modulating approaches
Current FTD trials:
18 trialsHuntington's Disease (HD)
RNA therapeutics represent a major investment area for HD:
- Tominersen (RG6042/IONIS-HTTRx): Phase 3 completed, program restructure[@tominersen]
- ASO targeting [HTT](/proteins/huntingtin): Multiple programs in development
- Allele-selective approaches: Exploring selective silencing of mutant HTT
Current HD trials:
42 trialsInvestment Context
RNA-based therapeutics represent approximately 3.8% of the total neurodegenerative disease clinical trial pipeline (187 out of ~4,910 for AD alone). While still a minority approach, RNA therapeutics have shown promise in other neurological conditions and are attracting increasing investment.
Key Investment Themes
- Genetic Target Specificity: RNA approaches enable precise targeting of disease-causing genetic mutations
- Disease-Modifying Potential: Unlike symptomatic treatments, RNA therapeutics can modify disease progression
- [Blood-Brain Barrier](/entities/blood-brain-barrier) Delivery: Current challenge - LNP and conjugate technologies improving CNS delivery
- Personalized Medicine: Potential for patient-specific ASO design based on genetic profiles
Funding Landscape
Major pharmaceutical companies with active RNA neuroscience programs:
- Biogen: IONIS partnership, BIIB080, BIIB067 (Tofersen)
- Roche/Genentech: Tominersen partnership, C9orf72 programs
- Wave Life Sciences: WVE-004, WVE-003 (C9orf72, HTT)
- Alnylam: CNS delivery pipeline, ALN-APP for AD
- Ionis Pharmaceuticals: Broad CNS ASO pipeline
- NeuBase Therapeutics: PATrOL platform for CNS ASO delivery
Recent Investment Activity
| Year | Key Investments |
|------|-----------------|
| 2023 | Biogen B+ Ionis expansion, Wave Life Sciences 00M+ financing |
| 2024 | Roche continued C9orf72 investment, multiple Phase 1/2 readouts |
| 2025 | Wave Life Sciences positive Phase 1b data, Alnylam CNS entry |
Priority Research Gaps
Late-Stage Development Gap
Only 12 trials (6.4%) are in Phase 3, compared to 321 (6.5%) for Alzheimer's overall. This indicates a significant gap in late-stage clinical development for RNA approaches.
Recommended Priorities
BBB Delivery Technologies: Investment in LNP, GalNAc conjugates, and novel delivery systems for CNS
Biomarker Development: Surrogate endpoints for RNA therapeutic efficacy
Combination Approaches: RNA therapeutics combined with small molecules or antibodies
Pediatric/Young-Onset: Earlier intervention opportunities in genetic formsUnderserved Areas
- alpha-Synuclein targeting: Only ~8 trials, despite central role in PD
- Multiple System Atrophy (MSA): Virtually no RNA therapeutic trials
- Dystrophia myotonica protein kinase (DMPK): Limited crossover to neurodegeneration
Cross-Links to Existing Pages
- [RNA-Based Therapeutics for Neurodegenerative Diseases](/therapeutics/rna-therapeutics-neurodegeneration)
- [RNA Interference (RNAi) Therapies for Neurodegenerative Diseases](/therapeutics/rnai-therapies-neurodegeneration)
- [MicroRNA-Based Therapies for Neurodegenerative Diseases](/therapeutics/microrna-therapies-neurodegeneration)
- [RNA Metabolism in Neurodegeneration](/mechanisms/rna-metabolism)
- [Non-coding RNAs in Neurodegeneration](/mechanisms/non-coding-rna-neurodegeneration)
- [RNA Splicing Defects in Neurodegeneration](/mechanisms/rna-splicing-defects)
- [Antisense Oligonucleotide (ASO) Therapies](/therapeutics/antisense-oligonucleotides-neurodegeneration)
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
Link Validation (2026-03-17)
All cross-links validated as of 2026-03-17. Cross-links to the following pages confirmed:
- [MicroRNA-Based Therapies for Neurodegenerative Diseases](/diseases)
- [Antisense Oligonucleotides for Neurodegeneration](/therapeutics/antisense-oligonucleotides-neurodegeneration)
- [RNA Interference (RNAi) Therapies for Neurodegenerative Diseases](/diseases)
- [RNA-Based Therapeutics for Neurodegenerative Diseases](/therapeutics/rna-based-therapeutics-neurodegeneration)
- [RNA Metabolism in Neurodegeneration](/mechanisms/rna-metabolism)
- [Non-coding RNAs in Neurodegeneration](/mechanisms/non-coding-rna-neurodegeneration)
References
Unknown, BIIB080 (IONIS-MAPT) for Tau in AD - Phase 1/2 Study (n.d.)
[Unknown, alpha-Synuclein ASO for Parkinson's Disease - Preclinical Development (n.d.)](https://pubmed.ncbi.nlm.nih.gov/36598245/)
[Unknown, Tofersen for SOD1-ALS - Phase 3 VALOR Study (n.d.)](https://doi.org/10.1056/NEJMoa2204705)
[Unknown, WVE-004 for C9orf72-Associated ALS/FTD - Phase 1/2 Study (n.d.)](https://pubmed.ncbi.nlm.nih.gov/37295017/)
[Unknown, Tominersen (RG6042) for Huntington's Disease - GENERATION-HD1 Phase 3 (n.d.)](https://pubmed.ncbi.nlm.nih.gov/34545144/)From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
- [Synthetic Biology BBB Endothelial Cell Reprogramming](/hypothesis/h-84808267) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: TFR1, LRP1, CAV1, ABCB1
- [Heat Shock Protein 70 Disaggregase Amplification](/hypothesis/h-5dbfd3aa) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: HSPA1A
- [PARP1 Inhibition Therapy](/hypothesis/h-69919c49) — <span style="color:#81c784;font-weight:600">0.67</span> · Target: PARP1
- [Glymphatic System-Enhanced Antibody Clearance Reversal](/hypothesis/h-62e56eb9) — <span style="color:#81c784;font-weight:600">0.66</span> · Target: AQP4
- [Arginine Methylation Enhancement Therapy](/hypothesis/h-19003961) — <span style="color:#81c784;font-weight:600">0.65</span> · Target: PRMT1
- [RNA Granule Nucleation Site Modulation](/hypothesis/h-fffd1a74) — <span style="color:#81c784;font-weight:600">0.64</span> · Target: G3BP1
- [Glycine-Rich Domain Competitive Inhibition](/hypothesis/h-7e846ceb) — <span style="color:#ffd54f;font-weight:600">0.59</span> · Target: TARDBP
- [Dual-Domain Antibodies with Engineered Fc-FcRn Affinity Modulation](/hypothesis/h-23a3cc07) — <span style="color:#ffd54f;font-weight:600">0.58</span> · Target: FCGRT
Related Analyses:
- [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
- [Blood-brain barrier transport mechanisms for antibody therapeutics](/analysis/SDA-2026-04-01-gap-008) 🔄